key: cord-0855155-17523sof
authors: Lineburg, Katie E.; Grant, Emma J.; Swaminathan, Srividhya; Chatzileontiadou, Demetra S.M.; Szeto, Christopher; Sloane, Hannah; Panikkar, Archana; Raju, Jyothy; Crooks, Pauline; Rehan, Sweera; Nguyen, Andrea T.; Lekieffre, Lea; Neller, Michelle A.; Marcus Tong, Zhen Wei; Jayasinghe, Dhilshan; Chew, Keng Yih; Lobos, Christian A.; Halim, Hanim; Burrows, Jacqueline M.; Riboldi-Tunnicliffe, Alan; Chen, Weisan; D’Orsogna, Lloyd; Khanna, Rajiv; Short, Kirsty R.; Smith, Corey; Gras, Stephanie
title: CD8+ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope cross-react with selective seasonal coronaviruses
date: 2021-04-13
journal: Immunity
DOI: 10.1016/j.immuni.2021.04.006
sha: 4caeb126b6a0f0cdbce5462885cf00e90fd0d690
doc_id: 855155
cord_uid: 17523sof

Efforts are being made worldwide to understand the immune response to SARS-CoV-2, the virus responsible for the COVID-19 pandemic, including the impact of T cell immunity and cross-recognition with seasonal coronaviruses. Screening SARS-CoV-2 peptide pools revealed that the nucleocapsid (N) protein induced an immunodominant response in HLA-B7+ COVID-19-recovered individuals that was also detectable in unexposed donors. A single N-encoded epitope that was highly conserved across circulating coronaviruses drove this immunodominant response. In vitro peptide stimulation and crystal structure analyses revealed T cell-mediated cross-reactivity towards circulating OC43 and HKU-1 beta coronaviruses, but not 229E or NL63 alpha coronaviruses, due to different peptide conformations. TCR sequencing indicated cross-reactivity was driven by private T cell receptor repertoires with a bias for TRBV27 and a long CDR3β loop. Together, our findings demonstrate the basis of selective T cell cross-reactivity towards an immunodominant SARS-CoV-2 epitope and its homologues from seasonal coronaviruses, suggesting long-lived protective immunity.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emerging virus responsible for the ongoing Coronavirus Disease 2019 pandemic. Over 97 million individuals have been infected and over 2 million individuals have succumbed to the viral infection . While some vaccines against SARS-CoV-2 are already being administered, and others are in development, many questions remain regarding the immune response toward this virus. Cytotoxic CD8 + T cells are key players in the immune response to viral infections, as they participate directly in viral clearance. Among the 26 viral proteins of SARS-CoV-2, some surface proteins, such as the spike protein (S), are more variable, while others are internal and more conserved such as the nucleocapsid protein (N). The sequence conservation of non-surface proteins makes them ideal vaccine targets for activating cytotoxic CD8 + T cells. CD8 + T cells recognise small peptides (typically 8-10 amino acids) together with Human Leukocyte Antigen (HLA) molecule with varying affinity. While HLA-A2, the most prevalent HLA molecule (~40% frequency worldwide (Ellis et al., 2000) ), can present SARS-CoV-2 N-derived peptides (Szeto et al., 2020) , they are only weakly immunogenic (Habel et al., 2020) . However, it remains unclear whether this is a characteristic specific to the selected N-derived peptides, as HLA-A2 + individuals also demonstrate a strong CD8 + T cell response to an S-derived epitope (Shomuradova et al., 2020) . Therefore, it is imperative to identify and characterise novel immunogenic CD8 + T cell epitopes against SARS-CoV-2.

Another important aspect of understanding the immune response toward this new coronavirus is to understand the properties of protective pre-existing immunity at a population level (Karlsson et al., 2020) . It has been proposed that pre-existing immune memory may be generated by previous infection with seasonal coronaviruses (OC43, 229E, NL63 and HKU-1) (Mateus et al., 2020; Ng et al., 2020) . However, the identity of the T cell epitopes that give rise to pre-existing immunity is only starting to emerge (Bacher et al., 2020; Braun et al., 2020; Karlsson et al., 2020; Le Bert et al., proteins of OC43 and HKU-1 and 23% with NL63 and 229E virus strains. The majority of this sequence homology occurs within the N-terminal domain of the protein, which also contains the immunogenic N 105-113 peptide (SPRWYFYYL, hereafter referred as SPR) (Ferretti et al., 2020; Kared et al., 2020; Peng et al., 2020; Schulien et al., 2020; Sekine et al., 2020; Snyder et al., 2020) . The SPR peptide sequence is identical between SARS-CoV-2 and SARS-CoV-1, differs by only one residue in OC43 and HKU-1 (LPRWYFYYL, hereafter referred as LPR), three residues in 229E (SPKLHFYYL, hereafter referred as SPK), and four in NL63 viruses (PPKVHFYYL, hereafter referred to as PPK).

Here, we demonstrated that HLA-B7 + individuals who had recently recovered from COVID-19 exhibited a dominant CD8 + T cell response that was highly specific to the SPR epitope of the SARS-CoV-2 N protein. In addition, we identified SPRspecific CD8 + T cells in multiple unexposed HLA-B7 + individuals which showed cross-reactivity with the homologous LPR peptide from the OC43 and HKU-1 strains.

However, this same cross-recognition did not extend to the similarly homologous SPK and PPK peptides from the 229E and NL63 viruses, respectively. Using the structural landscape of HLA-B7 bound to SPR and its variants, we delineate the molecular basis for selective T-cell cross-reactivity towards specific seasonal coronaviruses.

Although many CD8 + T cell studies have focused on different proteins or a limited number of selected peptides (Habel et al., 2020; Kared et al., 2020; Sekine et al., 2020; Shomuradova et al., 2020; Szeto et al., 2020) , the specific SARS-CoV-2 proteins that consistently elicit the strongest CD8 + T cell responses remain ill-defined (Ferretti et al., 2020; Grifoni et al., 2020; Nelde et al., 2021; Peng et al., 2020) . To assess this, we used peripheral blood mononuclear cells (PBMCs) derived from COVID-19-recovered individuals (n=37) to screen 13 overlapping peptide pools spanning 12 SARS-CoV-2 proteins (Figure 1 , Tables S1 and S2). While all 37 COVID-19-recovered donors displayed immunogenicity to SARS-CoV-2 peptide stimulation, ≥ 70% of donors demonstrated a CD8 + IFN-γ + response ≥ 5% when stimulated with ORF3A, N, S-1 or S-2 peptide pools (26 out of 37). The most consistent CD8 + T cell responses were generated against the N protein-derived peptide pool, in conjunction with the expression of HLA-B7 ( Figure 1A) . The majority (76%) of these HLA-B7 + individuals demonstrated a dominant CD8 + T cell response with an average IFN-γ + frequency ≥ 10% (13 out of 17). Conversely, only 25% of HLA-B7individuals displayed comparable responses (5 out of 20).

Significant differences in CD8 + T cell responses between HLA-B7 + and HLA-B7individuals were only observed in response to the N protein ( Figure 1B , p < 0.0001).

To assess whether CD8 + T cell reactivity to N protein was associated with the presence of elevated antibody titres, we examined neutralising anti-spike IgG titres in COVID-19-recovered individuals and did not observe any significant differences between HLA-B7 + and HLA-B7donors (n=37) (Figure 1C) . Similarly, the strong CD8 + T cell response was comparable between males (n=14) and females (n=23), and similar within donors categorised as younger (n=18) or older (n=19) than 50 years old. The distribution of disease severity reported was comparable between HLA-B7 + and HLA-B7cohorts (Table S2) .

In order to define the immunogenic peptide(s) responsible for this HLA-B7 + restricted N-specific CD8 + T cell response, we used a matrix of peptide pools to J o u r n a l P r e -p r o o f identify which specific peptide elicited the strongest IFN-γ response. Through this process, we identified an immunogenic hotspot (Figure 2 ) corresponding to the same N protein region that contains the known immunogenic HLA-B7 restricted SPR (N 105-113 ) epitope (Table S3 ) (Ferretti et al., 2020; Kared et al., 2020; Schulien et al., 2020; Sekine et al., 2020; Snyder et al., 2020) . Eighty percent of HLA-B7 + COVID-19recovered donors showed a strong CD8 + T cell response to this peptide (14 out of 17), consistent with other reports (Ferretti et al., 2020; Kared et al., 2020; Schulien et al., 2020; Sekine et al., 2020; Snyder et al., 2020) . Three additional subdominant HLA-B7-restricted epitopes from N protein were identified, namely RIR (N 93-101 ), FPR (N 66-74 ) and KPR (N 257-265 ) ( Figure 2B , Table S3 ). While FPR and KPR are known to be immunogenic in COVID-19-recovered individuals (Schulien et al., 2020) , RIR was predicted but not yet described as an immunogenic SARS-CoV-2 CD8 + T cell epitope (Sekine et al., 2020) .

Overall, these data show that the SARS-CoV-2 N protein contains multiple immunogenic epitopes that induce a strong CD8 + T cell response in COVID-19recovered HLA-B7 + individuals, and that the dominant CD8 + T cell response was directed against the SPR peptide.

Given that this dominant SPR-specific CD8 + T cell response was observed in HLA-B7 + individuals (Ferretti et al., 2020; Kared et al., 2020; Schulien et al., 2020; Sekine et al., 2020; Snyder et al., 2020) , and that pre-existing immunity towards this peptide has been suggested in unexposed individuals (Ferretti et al., 2020; Nelde et al., 2021; Schulien et al., 2020) , we next sought to identify the basis of the T cell cross-reactivity that elicits the cross-recognition observed against SARS-CoV-2.

Sequence alignment comparing SARS-CoV-2 with other coronaviruses demonstrated that although the entire N protein sequence homology is below 30%, the region containing the SPR peptide is more conserved, displaying 55-89% sequence homology ( Table 1) . The homologous peptides from SARS-CoV-1, OC43, HKU-1, 229E and NL63 share a proline at position 2 (P2-P) and a leucine at position 9 (P9-L).

These residues provide critical anchors for HLA-B7 binding (Sette and Sidney, 1999) , and therefore suggest that SPR peptide homologues from these seasonal viral strains might bind to the HLA-B7 molecule. Alignment of 26,158 N protein sequences from SARS-CoV-2 revealed a 100% conservation of the SPR peptide within circulating isolates including the variants isolated in the United Kingdom (B.1.1.7), South Africa (B.1.351), or Brazil (P.1) ( Table S4 ). In addition, circulating isolates of the homologous peptides (LPR, SPK, and PPK) are entirely conserved within their respective viruses (Table S4) , demonstrating their global conservation.

Considering the high degree of conservation between SPR and these homologous peptides (Table 1) , we investigated whether SARS-CoV-2-specific CD8 + T cells were able to cross-recognise any of the other conserved homologous peptides. We first expanded SPR-specific T cells from PBMCs isolated from COVID-19-recovered individuals (Figure 3) . Following re-stimulation of the SPR-specific CD8 + T cells with the SPR peptide, a high level of specificity for the SPR peptide was detected ( Figure 3A) , with an average CD8 + IFN-γ + response of 23.13%. These same CD8 + T cells were able to cross-react when restimulated with the LPR peptide ( Figure 3A) , resulting in a similar CD8 + IFN-γ + T cell response of 18.86%.

Conversely, we observed little to no reactivity when the SPR-specific CD8 + T cells were restimulated with the SPK or PPK peptide ( Figure 3A and Figure S1A ).

Since it was evident that CD8 + T cells were able to cross-recognise the variant peptides from selected seasonal coronaviruses, we next assessed the level of crossreactive CD8 + T cells in SARS-CoV-2 unexposed individuals. We expanded peptidespecific CD8 + T cells against each of the four peptide variants using PBMCs from unexposed donors (n=13 for SPR, LPR and SPK lines, and n=10 for PPK lines). After 10-14 days expansion, we re-stimulated with each of the individual peptide variants and assessed the ability of CD8 + T cells to produce IFN-γ using an intracellular cytokine staining (ICS) assay ( Figure 3B and 3C, Figure S1 ). Peptide-specific CD8 + T cells generated against SPR, LPR and SPK peptides were most specific for their cognate peptide ( Figure 3C , Figure S1 ), however, the T cells generated against the PPK peptide demonstrated limited specificity ( Figure 3C, Figure S1E ). Peptidespecific CD8 + T cells generated in response to either SPR or LPR peptide stimulation displayed cross-reactivity in the majority of unexposed donors without significant difference between the two peptides ( Figure 3C) . Conversely, those generated in J o u r n a l P r e -p r o o f response to SPK or PPK stimulation displayed little to no cross-reactivity. Functional avidity analysis confirmed comparable recognition of both SPR and LPR peptides by T cells generated from unexposed individuals, and furthermore it also indicated that SPR-specific T cells generated by COVID-19-recovered donors display significantly higher avidity ( Figure 3D, Figure S2A ), similar to that reported in CD4 + T cells (Bacher et al., 2020) . A higher magnitude of SPR-specific CD8 + T cells was observed from COVID-19-recovered donors (median: 16%) than from unexposed donors (median: 0.4%) ( Figure S2B ).

To assess the polyfunctionality of activated CD8 + T cells in response to peptide recall, we measured the production of IFN-γ, TNF, and IL-2 as well as CD107a expression. SPR-specific CD8 + T cells from COVID-19-recovered individuals exhibited broader polyfunctionality than those from unexposed donors, with the majority expressing three or four functions (IFN-γ, TNF, CD107a +/-IL-2) ( Figure 3E , Figure S3A ). In comparison, responses of unexposed individuals, irrespective of the peptide used, were dominated by CD8 + T cells generating one or two cytokines that included IFN-γ, TNF and/or CD107a but not IL-2 (Figures 3E and   S3 ).

These data demonstrate that both exposed and unexposed individuals can generate SPR-specific CD8 + T cells that efficiently cross-recognise the homologous LPR peptide from circulating beta-coronaviruses.

To further characterise these cross-reactive CD8 + T cells, we next assessed their TCR repertoires. SPR-specific CD8 + T cells from COVID-19-recovered donors were stained with the HLA-B7-SPR multimer and single-cell isolated by fluorescence activated cell sorting (FACS) ( Figure 4A ). Additionally, SPR-and LPR-specific T cells from unexposed individuals were individually stained with either the HLA-B7-SPR or HLA-B7-LPR multimer and single-cell sorted ( Figure S2C ). The TCR

repertoire was determined using RT-multiplex PCR (Grant et al., 2018; Wang et al., 2012) . A total of 767 T cells were sequenced from COVID-19-recovered (n=5) and J o u r n a l P r e -p r o o f unexposed (n=7) individuals. This analysis revealed that clonotypic diversity underpins the response to both SPR and LPR peptides, with a total of 209 clonotypes isolated and 80 unique αβ TCR pairs ( Table S5) . The TCR repertoires for each individual were private, with no shared (public) TCRs identified between individuals.

This suggests that the number of distinct clonotypes capable of responding to the SPR epitope likely underpins the consistent immunodominant response observed in convalescent participants. Cross-reactive CD8 + T cell clones recognising both the SPR and LPR peptides were observed in the majority of unexposed individuals (n=6/7). However, a unique clonotypic profile was evident in all donors' PBMC following SPR and LPR stimulation. This suggests that subtle differences in peptide recognition by different TCRs not only influence clonal expansion but also impact the efficiency and avidity of T cell cross-recognition towards homologous peptides ( Figure S2A ). Comparison of the SPR-specific T cell αβTCR sequences identified a strong TRBV usage bias, with 30% and 40% of these clonotypes expressing the TRBV27 gene in unexposed and COVID-19-recovered individuals, respectively, whereas the LPR-specific T cells displayed a bias for TRBV28 (22%, Figure 4B ). In comparison, α-chain sequencing revealed limited shared usage between COVID-19recovered and unexposed individuals ( Figure 4B) . A usage bias for TRAV8-2 in SPR-and LPR-specific clonotypes was seen in unexposed individuals, and a shared TRAV21 usage (~10-12%) in unexposed and COVID-19-recovered donors ( Figure   4B , Table S5 ). While we observed a typical distribution in CDR3α length, a preference for long CDR3β was seen in all populations, with the majority of identified sequences greater than 15 amino acids in length ( Figure 4C ). Although analysis of the CDR3 loop sequences did not reveal a shared motif in the α or β chains, reflecting the private nature of the TCR repertoires ( Figures S4) , a shared 108 PxxGx[P/G/A]x 114 motif (where x is any of V/T/S/L/G) was observed in the 18 residue-long CDR3β loops for the SPR-specific TCRs from both COVID-19recovered and unexposed donors ( Figure 4D ).

While not definitive, the presence of this shared motif in clonotypes from both exposed and unexposed donors suggests that the pre-existing immunity in HLA-B7 + individuals favoured clonal expansion.

To determine the molecular basis of this selective CD8 + T cell crossreactivity, we assessed the ability of the SPR and homologous peptides to form a stable complex with HLA-B7. Each peptide refolded efficiently with the HLA-B7 molecule, with the exception of the PPK peptide (poor yield). Next, the thermostability of each peptide-HLA (pHLA) complex was assessed ( Figure S5A ).

The most stable complexes identified were HLA-B7-SPR and HLA-B7-LPR (Tm ≥ 60°C), followed by HLA-B7-SPK (Tm ≈ 56°C), while the HLA-B7-PPK was less stable than the others (Tm ≈ 48°C) ( Table 1 ). Considering that both the SPR and SPK peptides demonstrated similar thermostability in complex with HLA-B7, but that CD8 + T cells were not able to cross-recognise both peptides, we next determined the crystal structures of these peptides bound to the HLA-B7 molecule ( Figure 5) .

The crystal structure of HLA-B7-SPR and HLA-B7-SPK were solved at 2.88Å and 1.97Å, respectively ( Table S6) residues) observed in 34% and 37% of the clonotypes in COVID-19-recovered and unexposed donors, respectively ( Figure 4C) , which would be able to contact a greater surface area of the peptide due to their length. In comparison, the conformation adopted by the SPK peptide only exposed three aromatic residues located at the Cterminal part of the peptide ( 6 FYY 8 ) ( Figure 5E ). The LPR peptide only differs from J o u r n a l P r e -p r o o f SPR at P1, and this single substitution is unlikely to change the peptide conformation,

given that HLA-B7 accommodates a wide range of residues at P1 based on previously reported structures (Brennan et al., 2012; Chan et al., 2018; Du et al., 2016; Rowntree et al., 2020; Rowntree et al., 2018) . Therefore, due to the high sequence identity, the LPR peptide is likely to adopt a similar conformation to the SPR peptide ( Figure 5F ), thus forming the basis of the CD8 + T cell cross-reactivity observed in HLA-B7 + individuals. Despite sharing 67% sequence identity, the different structures adopted by the SPR (SARS-CoV-2) and SPK (229E) peptides provide a basis for a low, if any, level of CD8 + T cell cross-reactivity between these peptides, highlighting the fine specificity of CD8 + T cells.

T cell mediated cross-reactivity in response to seasonal coronaviruses has the potential to limit both the development and severity of COVID-19. Here, we demonstrated that a robust CD8 + T cell response in HLA-B7 + individuals is primarily directed towards a single immunodominant epitope, SPR, encoded by the N protein of SARS-CoV-2, recognised by more than 80% of COVID-19-recovered donors tested.

We also identified SPR-specific CD8 + T cells in more than 90% of unexposed HLA-B7 + individuals tested, who had not been exposed to SARS-CoV-2. While comparative analysis of circulating seasonal coronaviruses revealed a high level of conservation in the homologous peptide sequences, including conservation of the critical proline residue at P2 of the epitope, detailed analysis revealed that T cell responses in unexposed volunteers were driven by cross-reactive CD8 + T cells specific for the LPR peptide from the OC43 and HKU-1 seasonal coronaviruses. It is possible that these cross-reactive memory CD8 + T cells facilitate the strong, polyfunctional, high avidity CD8 + T cell response towards the SPR peptide observed in T cells expanded from COVID-19-recovered individuals. In contrast, despite sharing the C-terminal 6 FYY 8 motif and the HLA-B7-favoured anchor residues (P2-P and P9-L) with the PPK and SPK peptides from 229E and NL63 viruses, respectively, there was no CD8 + T cell cross-reactivity between these and the SPR or LPR Studies have provided tantalising evidence that individuals not exposed to SARS-CoV-2 may harbour T cells capable of cross-recognising epitopes presented by both HLA class I and class II molecules (Bacher et al., 2020; Braun et al., 2020; Karlsson et al., 2020; Le Bert et al., 2020; Nelde et al., 2021; Schulien et al., 2020; Shomuradova et al., 2020) . However, several factors including: a lack of sequence conservation between several of the reported cross-reactive epitopes, the nonphysiological quantities of antigen used in detection assays, and the limited number of unexposed donors assessed, may all contribute to an overestimation in the prevalence of pre-existing T cell immunity when it comes to defining truly cross-reactive T cells that could protect against COVID-19. It is therefore critical that detailed analysis of the molecular characteristics that promote or limit T cell cross-reactive immunity is undertaken (Karlsson et al., 2020; Sette and Crotty, 2020) . It is well-established from studies in other human viral infections, including HIV, CMV and influenza, that even a single amino acid change, particularly in a TCR contact region, can have a profound impact on cross-reactivity (Geldmacher et al., 2009; Goulder et al., 1997; Gras et al., 2010; Gras et al., 2009; Iglesias et al., 2011; Kloverpris et al., 2015; Smith et al., 2014 ). Here, we revealed different conformations of the SPR and SPK peptides in complex with HLA-B7, providing a basis for the low or lack of T cell cross-reactivity observed. This shows that despite the sequence similarity and conserved C-terminal motif between the peptides, T cell cross-reactivity will not occur towards all seasonal coronaviruses due to fine TCR specificity. Although we were unable to solve the structure of the LPR epitope in complex with HLA-B7, our modelling revealed significant structural homology, with minimal changes induced by the S to L substitution at P1. Similarly, SPR and LPR-specific T cells efficiently crossrecognised both peptides, displaying similar functional avidity and polyfunctionality.

TCR sequence analysis of SPR-and LPR-specific T cells revealed that while some biased gene usages were observed (TRAV8-2, TRBV2, TRBV27, TRBV28), the TCR repertoires were entirely private with no public TCR shared between individuals.

However, we observed key TCRs able to cross-react towards the SPR and LPR peptides in unexposed individuals. This likely contributes to the strong response J o u r n a l P r e -p r o o f observed from COVID-19-recovered donors' expanded T cells, and may suggest a level of pre-existing immunity. While the TCR repertoire was private, we observed a biased TRBV27 gene usage with long CDR3β loops preferentially expressed for SPRspecific TCRs in both unexposed and COVID-19-recovered individuals. Despite sequence diversity in the TCR repertoire, the biased for long length of the CDR3 loops might reflect a common docking mechanism between the clonotypes, and facilitate the recognition of the numerous large aromatic residues of the SPR peptide.

Altogether, it is clear that while pre-existing immunity towards SARS-CoV-2 exists, and may provide an advantage to certain individuals, this same advantage might be limited to a few epitopes specific to certain HLA molecules, and dependent upon previous encounter with certain coronaviruses. In addition, the presence of preexisting immunity suggests that memory T cells could be activated upon SARS-CoV-2 infection, important for long-lived protection that will be critical for vaccination (Canete and Vinuesa, 2020; Dan et al., 2020; Jarjour et al., 2020) . Those crossreactive T cells could also be used as biomarkers to help predict the severity of disease, or the efficacy of a vaccine. The discovery of defined epitopes that elicit strong CD8 + T-cell responses, particularly those that are pre-existing, is important as these epitopes could be exploited to boost or prime the immune response in a vaccination strategy, and as such could provide significant protection to the global population.

Overall, our study has established that one single epitope dominates the response towards the SARS-CoV-2 Nucleocapsid protein in HLA-B7 + individuals recovered from COVID-19. Although HLA-B7 is the most common HLA-B molecule in populations of European decent, it is the 6 th most frequent HLA-B molecule worldwide and is expressed at a frequency of 4% globally. Therefore, while generalisation at the global population level is not possible, due to our focus on a single allele, our study does provide a potential mechanism for the immunodominant response observed in HLA-B7 + individuals via cross-recognition by seasonal coronavirus T cells. Given the conservation between SARS-CoV-2 and seasonal J o u r n a l P r e -p r o o f coronaviruses, especially with beta-coronaviruses, it is likely that pre-existing and cross-reactive T cell responses would occur for other peptides restricted to diverse

HLAs. However, our study also demonstrates how even a few changes in amino acid sequence can impact T cell recognition, suggesting that the presence of immunodominant cross-reactive CD8 + T cells could be restricted to specific peptide-HLA complexes. More detailed and precise research in this direction is critical to determine the actual presence of cross-reactive and pre-existing T cells between SARS-CoV-2 variants and seasonal coronaviruses, and the potential role they could play in protection against COVID-19.

The authors declare no competing interests.

We worked to ensure gender balance in the recruitment of human subjects. We worked to ensure that the study questionnaires were prepared in an inclusive way.

One or more of the authors of this paper self-identifies as living with a disability. The author list of this paper includes contributors from the location where the research was conducted who participated in the data collection, design, analysis, and/or interpretation of the work. Figure   S6 and Table S3 . Figure S5 and Table   S6 .

J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f

Resource Availability

Further information and requests for resources and materials should be directed to the Lead Contact, Prof. Stephanie Gras (S.Gras@latrobe.edu.au)

Materials are available upon reasonable request.

The final crystal structure models for the peptide-HLA-B Table S1 .

PBMCs were separated from whole blood or buffy coats using density gradient centrifugation. PBMCs were used fresh or were cryogenically stored until use.

CD8 + T cell lines were generated as previously described (Grant et al., 2018; Lineburg et al., 2020) . Cytokine detection levels identified in the no-peptide control condition were subtracted from the corresponding test conditions in all summary graphs to account for non-specific, spontaneous cytokine production.

CD8 + T cell lines were multimer stained for 1 hr at room temperature. Cells were washed and surface stained with anti-CD8-PerCP-Cy5.5 (BD Biosciences), anti-CD4-BUV395 (BD Biosciences) anti-CD14-APCH7, anti-CD19-APCH7 and Live/Dead

Fixable Near-IR Dead Cell Stain (Life Technologies). Cells were either fixed with 1% paraformaldehyde and acquired on the BD LSR Fortessa, or were directly single-cell sorted into PCR plates (Eppendorf) using a BD Aria Fusion. Plates were centrifuged, and stored at -80°C until use.

Single-cell multiplex PCR was carried out as previously described (Grant et al., 2018; Wang et al., 2012) . Briefly, cDNA was generated using the VILO cDNA synthesis kit (Invitrogen) at 1/20 of the manufacturer's recommendation with 0.1% Triton X.

Nested PCR comprising 40 αand 27 β-chains was subsequently undertaken. PCR products were purified using ExoSAP (GE Healthcare) and were sequenced at AGRF (Melbourne, Australia) or The QIMR Berghofer Sequencing Facility (Brisbane, Australia). Sequences were analysed using FinchTV (Geospiza) and IMGT software (Brochet et al., 2008; Giudicelli et al., 2011) . CDR3 sequences shown are all productive (no stop codons). KI. These crystals were soaked in a cryoprotectant containing mother liquor and 20%

EG or 30% PEG3350 (w/v) and then flash-frozen in liquid nitrogen. The data were collected on the MX2 beamline at the Australian Synchrotron, part of ANSTO, Australia (Aragao et al., 2018) . The data were processed using XDS (Kabsch, 2010) and the structures were determined by molecular replacement using the PHASER Table S6 . All molecular graphics representations were created using PyMOL.

Model building of the structure of HLA-B7-LPR complex was performed using the crystal structure of HLA-B7-SPR as a starting model. The SPR peptide P1-Ser residue was mutated into a P1-Leu residue using the crystallographic software, COOT (Emsley et al., 2010) , where the side chain rotamer was selected based on the least steric clashes, as evaluated using MolProbity.

Vero cells were cultured in 96 well plates. Convalescent serum harvested from COVID-19-recovered patients was heat-treated at 56°C for 1 hour. The sera was then serial diluted with minimum essential medium (MEM) (Gibco) supplemented with 2% FCS. In physical containment 3 settings, the diluted sera were incubated with the SARS-CoV-2 (QLD/02; MOI 1) for 1 hour at room temperature. The serum-virus mixture was transferred to the cultured vero cells and further incubated for 1 hour at room temperature for infection. The inoculum was then removed and replaced with MEM (Gibco) supplemented with 2% FCS (Gibco). The cells were incubated at 37°C

for 72 hours. The cells were fixed with 10% formaldehyde for 24 hours.

Cells were permeabilised with PBS containing 0.1% Trition-X-100 (Sigma) for 15mins at room temperature. The plates were blocked using PBS (Sigma) supplemented with 0.1% Tween-20 (Sigma) and 3% skim milk for 1 hour at room temperature. The cells were primarily stained with rabbit anti-NP (1:3000)(Sino Biological) for 1 hour at room temperature. The plates were washed with PBS (Sigma) supplemented with 0.1% Tween-20 (Sigma). The cells were stained using goat anti-rabbit immunoglobulin horse-radish protein (HRP) (Thermo Fischer)

(1:3000) for 1 hour at room temperature. The plates were washed with PBS (Sigma) supplemented with 0.1% Tween-20 (Sigma). The plates were incubated with 2,2'azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS) (Thermo Fischer) substrate for colour development and incubated for 20 minutes. Measurements were done at 405 nm.

J o u r n a l P r e -p r o o f

Complete full length protein sequences for the SARS-CoV-2 (taxid ID 2697049, 419 amino acids), SARS-CoV-1 (taxid ID 694069, 422 amino acids), OC43 (taxid ID 31631, 448 amino acids), HKU-1 (taxid ID 290028, 441 amino acids), 229E (taxid ID 11137, 389 amino acids) and NL63 (taxid ID 277944, 377 amino acids) coronaviruses were obtained from the NCBI virus database http://www.ncbi.nlm.nih.gov/labs/virus on the 10th of November 2020. Sequences were aligned using https://www.fludb.org/brc/home.spg?decorator=influenza. All sequences were used except a single SARS-CoV-2 North American sequence that was unable to be aligned, and a single SARS-CoV-2 Europe sequence with an unknown amino acid (denoted as X) within the peptide sequence.

GraphPad Prism 8.2.1 (San Diego, CA) was used to perform statistical analysis.

Statistical comparisons between participant groups (unexposed and COVID-19recovered) were made using unpaired Mann-Whitney U Wilcoxon rank-sum tests. p < 0.05 was considered statistically significant.

J o u r n a l P r e -p r o o f

The CCP4 suite: programs for protein crystallography

MX2: a high-flux undulator microfocus beamline serving both the chemical and macromolecular crystallography communities at the Australian Synchrotron

Low-Avidity CD4(+) T Cell Responses to SARS-CoV-2 in Unexposed Individuals and Humans with Severe COVID-19

SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19

The impact of a large and frequent deletion in the human TCR beta locus on antiviral immunity

IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis

COVID-19 Makes B Cells Forget, but T Cells Remember

Divergent T-cell receptor recognition modes of a HLA-I restricted extended tumour-associated peptide

Immunological memory to SARS-CoV-2 assessed for greater than six months after infection

An interactive web-based dashboard to track COVID-19 in real time

HIV-1-Specific CD8 T Cells Exhibit Limited Cross-Reactivity during Acute Infection

Frequencies of HLA-A2 alleles in five U.S. population groups. Predominance Of A*02011 and identification of HLA-A*0231

Features and development of Coot

Unbiased Screens Show CD8(+) T Cells of COVID-19 Patients Recognize Shared Epitopes in SARS

CoV-2 that Largely Reside outside the Spike Protein

Minor viral and host genetic polymorphisms can dramatically impact the biologic outcome of an epitope-specific CD8 T-cell response

IMGT/V-QUEST: IMGT standardized analysis of the immunoglobulin (IG) and T cell receptor (TR) nucleotide sequences

Allele frequency net database (AFND) 2020 update: gold-standard data classification, open access genotype data and new query tools

Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS

Broad CD8(+) T cell crossrecognition of distinct influenza A strains in humans

Crossreactive CD8+

influenza A viruses

Structural bases for the affinity-driven selection of a public TCR against a dominant human cytomegalovirus epitope

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

CoV-2-specific CD8(+) T cell response associated with the prominent HLA-A*02:01 phenotype

Escape from highly effective public CD8+ T-cell clonotypes by HIV

T Cell Memory: Understanding COVID-19

Xds

The known unknowns of T cell immunity to COVID-19

A molecular switch in immunodominant HIV-1-specific CD8 T-cell epitopes shapes differential HLArestricted escape

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls

Rapid detection of SARS-CoV-2-specific memory

Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans

Phaser crystallographic software

SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition

Preexisting and de novo humoral immunity to SARS-CoV-2 in humans

Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19

A Shared TCR Bias toward an Immunogenic EBV Epitope Dominates in HLA

-Expressing Individuals

Inability To Detect Cross-Reactive Memory T Cells Challenges the Frequency of Heterologous Immunity among Common Viruses

Characterization of pre-existing and induced SARS-CoV-2-specific CD8(+) T cells

Pre-existing immunity to SARS-CoV-2: the knowns and unknowns

Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism

Epitopes Are Recognized by a Public and Diverse Repertoire of Human T Cell Receptors

Molecular imprint of

Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels

Balancing selection and heterogeneity across the classical human leukocyte antigen loci: a meta-analytic review of 497 population studies

The Presentation of SARS-CoV-2 Peptides by the Common

T cell receptor alphabeta diversity inversely correlates with pathogen-specific antibody levels in human cytomegalovirus infection

• ICS assay detects SARS-CoV-2-specific T cells in unexposed and recovered donors • Epitope mapping identifies one dominant HLA-B7-restricted epitope • Identical TCR clonotypes recognize SARS-CoV-2 and beta coronaviruses

The impact of seasonal coronaviruses on immune responses to SARS-CoV-2 is an active area of research. Here, Lineburg et al identify CD8 + T cells specific for a conserved and immunodominant SARS-CoV-2 epitope in HLA-B7 + individuals. Furthermore, SARS-CoV-2 epitope-specific CD8 + T cells display cross-reactivity to beta but

The authors would like to thank Queensland Health Forensic & Scientific Services, Queensland Department of Health who provided the SARS-CoV-2 isolate QLD02;Monash Facilities (Flow Core, Macromolecular Crystallisation Facility, Imaging Facility); VTIS, PathWest Laboratory Medecine and CareDx for HLA Typing; MX